Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

PathGroup Chooses Proscia To Deliver Next Generation Of Cancer Diagnosis For Millions of Patients


“We are thrilled that Proscia shares our vision for a fully digital future,” said Ben W. Davis, MD, CEO of PathGroup.

Proscia®, a leading provider of digital and computational pathology solutions, today announced that PathGroup, one of the largest providers of anatomic, clinical, digital, and molecular pathology services in the United States, will advance the 150-year-old standard of diagnosis for diseases like cancer with Concentriq® Dx. PathGroup is expanding its operations with Proscia’s software platform to further enhance the delivery of fast, high quality results for millions of patients, helping to better inform treatment decisions.

Up to 70% of clinical decisions depend on pathology.[1] Digital pathology shifts diagnosis from microscope to whole slide image, unlocking insights previously unseen by the human eye to realize the promise of precision medicine. It also drives powerful efficiency gains that are helping laboratories to overcome a range of systemic challenges; the number of cancer cases is expected to rise 47% between 2020 and 2040[2] while only 65% of pathology groups looking to hire could fill all open roles in 2021[3].

“Taking this next step on our journey requires a company to serve as our trusted partner and a platform that will grow across our network,” said Ben W. Davis, MD, CEO of PathGroup. “After a robust evaluation, we are thrilled that Proscia shares our vision for a fully digital future and confident that Concentriq Dx will enable us to rapidly expand upon our existing digital pathology foundation. With Proscia’s nimbleness and speed to innovation, we will leverage the latest technology, including AI, to provide the next generation of diagnosis for millions of patients.”

Concentriq Dx* is a modern pathology platform that drives routine diagnosis for laboratory networks of all sizes. By streamlining collaboration and enabling remote image viewing, it empowers pathologists to deliver higher quality results through broadened access to expertise. The platform also offers world-class interoperability with leading scanners and image analysis applications and is designed for realizing the promise of pathology’s AI-powered future to meet evolving needs.

“PathGroup’s transition to Concentriq Dx is a testament to the platform’s ability to deliver on the full promise of digital pathology at scale,” said David West, Proscia’s CEO. “Pathology data is one of healthcare’s most valuable assets, and PathGroup is now well-positioned to fully capitalize on its potential to transform patient care.”

One of the largest comprehensive pathology services providers, PathGroup currently supports more than 15,000 referring physicians and over 200 hospital customers with diversified laboratory testing services and high-touch customer service. Its team of more than 225 pathologists represents every pathology subspecialty. PathGroup operates a fully digital primary diagnosis approach at its centralized laboratory in Nashville, Tennessee.

“Digital pathology is quickly becoming synonymous with pathology,” said Steve Holloway, Company Director at Signify Research. “As leading laboratories like PathGroup grow their implementations, they continue to set a new standard of diagnosis.”

*Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US during the COVID-19 public health emergency.

About PathGroup

Founded in 1965, PathGroup is a premier provider of anatomic, clinical, molecular, and digital pathology services in the United States. Privately held and physician-centric, PathGroup works seamlessly with customers to provide superior diagnostic services – a vital link in the cycle of patient relationships. PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results. The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers, and most importantly, patients. One Lab; Total Service. For more information, visit pathgroup.com.

About Proscia

Proscia is a software company that is accelerating pathology’s digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate discovery, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies rely on Proscia’s software each day. For more information, visit proscia.com.

[1] NHS England (2017). Digital First: Clinical Transformation Through Pathology Innovation. National Pathology Programme; doi: https://www.england.nhs.uk/wp-content/uploads/2014/02/pathol-dig-first.pdf

[2] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660

[3] Gross, D. et al (2022). Strong Job Market for Pathologists: Results From the 2021 College of American Pathologists Practice Leader Survey. Arch Pathol Lab Med 2022; doi: https://doi.org/10.5858/arpa.2022-0023-CP

Share article on social media or email:

Highmark Health, Allegheny Health Network Unveil North Fayette Health + Wellness Pavilion


News Image

“This investment in Pittsburgh’s western suburbs is an exciting expansion of our footprint, and we look forward to the remarkable health experiences that it will provide to those who seek care here,” said Bruce Meyer, MD, Executive Vice President and Western PA Market President, Highmark Health.

Representatives of Highmark Health and Allegheny Health Network (AHN) today joined community leaders for a ceremonial ribbon-cutting to celebrate the launch of AHN’s North Fayette Health + Wellness Pavilion – a state-of-the-art facility offering an array of primary and specialty outpatient services anchored by the network’s Center for Reproductive Medicine.

The new $70 million, 68,000-square-foot AHN facility, located at 200 Quinn Drive in North Fayette Township, will officially open to patients on Monday for most services being offered at the location. AHN’s Center for Reproductive Medicine will open to patients in May.

“Today marks the latest milestone for AHN and Highmark Health in our ongoing journey to transform health care for patients and their families in the communities where they live and work,” said Bruce Meyer, MD, Executive Vice President and Western PA Market President, Highmark Health. “This investment in Pittsburgh’s western suburbs is an exciting expansion of our footprint, and we truly look forward to the remarkable health experiences that it will provide to those who seek care here.”

AHN North Fayette will serve as the new home base for AHN’s comprehensive Center for Reproductive Medicine, a leading reproductive endocrinology program and licensed ambulatory surgery facility for infertility treatments. The AHN reproductive medicine team will work exclusively from the new location to provide tailored plans, from initial consultation through prescribed care journey, which could include ovulation-stimulating medications, in vitro fertilization (IVF), intrauterine insemination, and sperm testing, among other infertility therapies.

AHN worked closely with clinicians, architects and buildings designers to create a world-class facility centered around the patient experience. AHN North Fayette features a separate, distinct entrance for women undergoing infertility treatments. Inside, the center is equipped with private, spacious waiting areas and exam rooms – away from obstetric patients, families, and those who may be expecting.

“Thoughtful collaboration among our teams has resulted in a beautiful, patient-centered design that considers the deeply complex health journey of these patients, both physically and emotionally,” said Marcia Klein-Patel, MD, PhD, Chair of AHN Women’s Institute, “With their own entrance and separate facilities, women undergoing infertility procedures are welcomed in an appropriate, calming environment and will be among those who are on similar care paths.”

The surgical center, post-op area and outpatient labs are also accessed via a designated entrance and exit. For patients accessing primary care or other specialty outpatient services, the facility’s main entrance will direct them to a centralized registration hub.

Additional clinical services offered at the Pavilion include primary care, behavioral health for adults and children, including AHN Women’s Behavioral Health; a full spectrum of diagnostic imaging capabilities; and onsite specialists in orthopedics, endocrinology, rheumatology, obstetrics and gynecology services; as well as physician-led rotating specialty clinics for maternal-fetal medicine, urogynecology, cardiology, gastroenterology, pulmonology, neurology and neurosurgery, pain medicine, bariatrics and podiatry.

Express care and walk-in services will also be available at the Pavilion for extended and weekend hours starting in May, complemented by an on-site laboratory and advanced imaging suite. AHN North Fayette will house one of the area’s first 3T MRI scanners – a leading-edge technology that produces exceptionally detailed images of the anatomy. CT, ultrasound, DEXA bone density scanner, Xray and mammography are also available at the Pavilion.

“The opening of this magnificent facility is yet another example of our Living Health model coming to life through more convenient community access to services, through innovative solutions and care pathways that help patients live their best lives and through leading clinical expertise across every discipline,” said Jim Benedict, chief operating officer at AHN.

AHN partnered with Orangestar Property Advisors and Sentinel Construction to develop the North Fayette Health + Wellness Pavilion. RM Creative served as the project architect.

North Fayette will become AHN’s sixth Health + Wellness Pavilion, joining others serving the communities of Wexford, Bethel Park, Peters Township and Erie’s east and west sides. Today’s ribbon-cutting comes on the heels of the opening of AHN’s Montour Sports Medicine complex in November 2022, AHN Seneca Valley outpatient center in August 2022, and AHN Wexford hospital in September 2021.

Link to facility images here.

About the Allegheny Health Network:

Allegheny Health Network (AHN.org) is an integrated healthcare delivery system serving the greater Western Pennsylvania region. The Network is composed of 14 hospitals, ambulatory surgery centers, Health + Wellness Pavilions, multiple employed physician organizations, home and community based health services, a research institute, and a group purchasing organization. The Network provides patients with access to a complete spectrum of advanced medical services, including nationally recognized programs for primary and emergency care, trauma care, cardiovascular disease, organ transplantation, cancer care, orthopedic surgery, neurology and neurosurgery, women’s health, diabetes, autoimmune disease and more. AHN employs approximately 22,000 people, has more than 2,600 physicians on its medical staff and serves as a clinical campus for Drexel University College of Medicine and the Lake Erie College of Osteopathic Medicine.

Flourish Medical CEO Presents at LSI Emerging MedTech Summit


Joanne Rupprecht, CEO of Flourish Medical, LLC, will present a novel women’s health medical device at this year’s LSI Emerging MedTech Summit

Joanne Rupprecht, CEO of Flourish Medical, will present a novel women’s health medical device at this year’s LSI Emerging MedTech Summit.

Flourish designs and manufactures a single-use disposable device that helps women manage stress urinary incontinence, a condition affecting more than 15 million women in the United States alone.

Joanne Rupprecht, CEO of Flourish Medical, LLC, will present a novel women’s health medical device at this year’s LSI Emerging MedTech Summit, taking place March 21-23 in Dana Point, California.

Flouish, dedicated to meeting the needs of the women’s health market, is the designer and manufacturer of a single-use disposable device that helps women manage stress urinary incontinence (SUI). Affecting more than 15 million women in the United States alone, stress incontinence is a condition that can affect women in many stages of life, and is the most common form of urinary incontinence.

At the summit, which connects medtech leaders with investors, Rupprecht will detail the SUI market, the lack of existing solutions for the SUI problem, and how Flourish is positioned to leverage current opportunities.

“In Flourish Medical, we have in place what we need to commercialize the device: an experienced team, a detailed plan, tremendous intellectual property and a clear path to regulatory approval,” says Rupprecht. The company is seeking $1.5 million in its seed round of funding, and $5 million in Series A funding upon FDA 510(k) clearance.

“The Flourish device means a positive lifestyle change for millions of women,” says Rupprecht. Research shows that fewer than 25% of women with incontinence seek medical advice or help for their problem, she explains, and that many of them are not candidates for surgery. Others simply prefer not to have surgery or an invasive procedure. “Flourish provides the chance for these women to easily manage this condition and engage in all the activities they wish to, without worry.”

Flourish Medical, LLC (http://www.flourish-medical.com)

Flourish Medical, LLC, is a medical device development and manufacturing company serving the needs of the women’s health market. The company’s flagship product, Flourish, is a novel, single-use, disposable device that helps women manage stress urinary incontinence. Flourish Medical is based in Boulder, Colorado.

Share article on social media or email:

Mount Sinai Expert Urge Colon Cancer Awareness and Education to Reverse Decline in Screening Rates during Pandemic


Colorectal cancer is the second leading cause of cancer deaths in both men and women in the United States. Although highly treatable and preventable, about 140,000 Americans are diagnosed and more than 50,000 people die each year, according to the Centers for Disease Control and Prevention (CDC). The United States Preventative Task Force recommends starting age of screening from 45 to 50.

More than 93% of colorectal cancer cases occur in people 45 years old or older. More than 75-90% of colorectal cancer cases can be avoided through early detection and removal of pre-cancerous polyps, and as many as 60% of colorectal cancer deaths could be prevented if men and women over the age of 45 were screened routinely.

In an effort to increase awareness and screening, Mount Sinai has expanded Colorectal Cancer Awareness Initiatives across all eight hospital sites during the month of March to provide patients with access to health professionals to discuss prevention, screening options, and risk factors. Mount Sinai experts will be available from various expertise to answer questions on diet, genetic counseling, the colonoscopy procedure and ways to schedule and support offered after diagnosis, and more.

Experts available for interview:

David Greenwald, MD, Director of Clinical Gastroenterology and Endoscopy at The Mount Sinai Hospital; Steven Itzkowitz, MD, Professor of Medicine and Oncological Sciences at the Icahn School of Medicine at Mount Sinai and Chair of the National Colorectal Cancer Roundtable; Laura Manning, MPH, RD, CDN, Clinical Nutrition Coordinator in the Department of Gastroenterology at The Mount Sinai Hospital; and Randolph Steinhagen, MD, Professor of Colon & Rectal Surgery at The Mount Sinai Hospital

Prevention Tips:


  • Schedule a Screening: a colonoscopy is the preferred screening method as it allows for both detection and removal of precancerous polyps during the same procedure. Other screening options include a flexible sigmoidoscopy, CT colonography, and home-based stool tests including the fecal occult blood test (FOBT), fecal immunochemical test (FIT), and a combined fecal immunochemical test with DNA test (FIT-DNA test). Individuals should discuss all of these options with their doctor to find which method works best for their lifestyle.

Know Your Risk Factors:

  • Age – More than 90% of colorectal cancer cases occur in people 45 years old or older and death rate increases with age.
  • Family history – As many as 1 in 3 people who develop colorectal cancer have other family members who have been affected by this disease. The risk is even higher if a relative was diagnosed under age 50 or if more than one first-degree relative (parent, sibling, child) has been affected.
  • Racial and ethnic background – Colorectal cancer affects people of all races and ethnicities. However, colorectal cancer disproportionately affects the Black community, where the rates are the highest of any racial/ethnic group in the US. African Americans are 20% more likely to get colorectal cancer and about 40% more likely to die from colorectal cancer than most other groups. Colorectal cancer screening rates remain lowest among Black and Hispanic/Latino communities.
  • Lifestyle factors – Common lifestyle factors that may increase colorectal cancer risk include: obesity; cigarette smoking; lack of exercise; overconsumption of fat, red and processed meats; not eating enough fiber, fruits and vegetables; and drinking alcohol excessively.
  • Pre-existing health conditions – Inflammatory bowel diseases (IBD), such as ulcerative colitis or Crohn’s disease, and less common genetic syndromes, such as familial adenomatous polyposis (FAP) or Lynch syndrome, significantly increase the risk of developing colorectal cancer. These patients are recommended to start screening at a younger age and more frequently.

Warning Signs & Symptoms:

  • A change in bowel habits, such as diarrhea, constipation or narrowing of the stool, lasting for more than a few days
  • Rectal bleeding, dark stools or blood in the stool
  • Cramping or abdominal pain
  • Weakness and fatigue
  • Unintended weight loss

Colon Cancer Screen Events in March:

  • March 2nd – Mount Sinai Beth Israel- Linsky Lobby – 281 1st Ave., New York NY 10003
  • March 7th – Mount Sinai West – Main Lobby – 1000 Tenth Avenue, New York, NY 10019
  • March 9th – Mount Sinai Morningside – Ambulatory Care Center Lobby – 440 W 114th St., New York, NY 10025
  • March 14th – Ansonia – Primary Care Physicians – 2nd Floor Lobby – 2109 Broadway 2nd Floor, New York, NY 10023
  • March 16th – Mount Sinai Union Square – 2nd Floor – 10 Union Square, New York, NY 10003
  • March 21st – The Mount Sinai Hospital- Guggenheim Pavilion – 1468 Madison Ave, New York, NY 10029
  • March 28th – Upper West Side – Upstairs Lobby – 230 West 74th Street, New York, NY 10023
  • March 31st – Mount Sinai Brooklyn – Main Lobby – 3201 Kings Hwy Brooklyn, NY 11234

The Mount Sinai Health System

The Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, over 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it. Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Share article on social media or email:

HotelPlanner Partners with the Vegan Women Summit as their Exclusive Hotel Provider


News Image

HotelPlanner, a leading travel technology platform and hotel booking engine, today announced a service provider partnership with the Vegan Women Summit (VWS), produced in partnership with Spire, to be the exclusive hotel provider and sponsor for their flagship annual event in New York City from May 18 – 20, 2023.

The Vegan Women Summit, founded by Jennifer Stojkovic, is a leading global destination for the future of food, fashion, beauty, and beyond. With more than 50,000 members across 31 countries on six continents, the VWS mission is to inspire, educate, and empower future and rising women leaders on how to bring compassion to their career and industry. The event brings together the world’s most powerful CEOs, celebrities, athletes, investors, activists, and more, for one common purpose: empowering the next generation of women changemakers to build a kinder, more sustainable world. Previous speakers include Clueless actor Alicia Silverstone, celebrity chef Charity Morgan, actor and influencer Tabitha Brown, and Suzy Amis Cameron, founder of the One Meal a Day movement, to name a few.

“We take tremendous pride in supporting a globally recognized women’s empowerment organization and their signature event to deliver a customized hotel booking solution for all attendees,” says Philip Ballard, Chief Communications Officer, HotelPlanner. “We hope to expand this partnership in the coming years as the VWS continues to grow globally.”

“We are incredibly fortunate to have travel and hospitality experts HotelPlanner support our flagship event with curated hotels that are eco-friendly and with plant-based restaurants nearby. That’s an incredible value add to our event,” says Jennifer Stojkovic, CEO, Founder, Vegan Women Summit. “As VWS continues to expand both nationally and globally, we look forward to expanding our partnership with HotelPlanner in the future.”

“As the producer of The Vegan Women Summit, it is important to work with plant-based and eco-conscious businesses and vendors,” says Talita Trygsland, Founder & CEO, SPIRE. “Through this event, we’re working together to advance the global sustainability agenda. This is incredibly important work for our planet and industry.”

For social media promotions, please use hashtag: #VWS2023 and tag @VegWomenSummit and @HotelPlanner.

###

About Vegan Women Summit

Vegan Women Summit (VWS) is a global events and media organization created to empower women to build a kinder, more sustainable world. VWS hosts several events per year with the goal to foster conversation amongst ambitious rising leaders working to bring compassion to their careers. VWS strives to provide an inclusive environment for all. Attendees of all backgrounds and genders are invited to participate in the growing VWS community.

To learn more, visit http://www.veganwomensummit.com

About HotelPlanner

HotelPlanner is a leading travel technology company and hotel booking engine that serves all traveler hotel needs from a single platform. HotelPlanner is one of the world’s top providers of individual, group, and corporate travel bookings, specializing in unique “Closed User Group” discount rates. Founded in 2003, HotelPlanner has enduring partnerships with the world’s largest Online Travel Agencies, well-known hotel chains, individual hotels, online wedding providers, ancillary lodging providers, corporations, sports franchises, universities and government agencies.

Learn more at https://www.hotelplanner.com

Share article on social media or email:

Gladskin, a Leading Eczema Skincare Brand, Introduces New Body Lotion that Helps to Maintain and Repair the Skin Barrier for Eczema-Prone Skin


Gladskin Eczemact™ Body Lotion

Today, Gladskin, a leading international skincare brand, announced the launch of its Eczemact™ Body Lotion, which provides 24-hour hydration to dry, dehydrated, eczema-prone skin. The new body lotion is hypoallergenic, paraben-free, fragrance-free and steroid-free. It joins the suite of Gladskin’s newly branded Eczemact™ products. With science developed in Switzerland, the Gladskin brand is known for its breakthrough endolysin technology, which addresses the skin microbiome’s’ role in eczema symptoms.

“We’re thrilled to add the Eczemact™ Body Lotion to our line-up of products built for people with eczema-prone skin,” said Skyler Stein, President of Gladskin USA. “There are an estimated 31 million people in the United States¹ that have eczema, which has no cure. Our revolutionary steroid-free products, including our body lotion, are a significant advancement in OTC products for people with dry, itchy, eczema-prone skin.”

The Gladskin Eczemact™ Body Lotion is dermatologically tested, minimally formulated, hypoallergenic, and fragrance-free. Formulated with squalane and ceramides, it moisturizes, replenishes skin lipids, and strengthens the skin barrier. Its lightweight, non-greasy feel and slather-friendly size are designed for regular daily use. It is available for purchase at Gladskin.com and retails at $26. For ultimate relief, pair the Body Lotion with Gladskin’s Eczema Cream, which contains Gladskin’s patented endolysin technology Micreobalance®.

“Moisturizing and repairing the skin barrier are crucial components of eczema care,” explained board certified dermatologist Dr. Peter Lio, MD, FAAD, Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern Feinberg School of Medicine. “I recommend Gladskin’s Eczcemact Body Lotion because it’s beautifully formulated with key ingredients to support the skin barrier—and almost nothing else!”

With the release of the Body Lotion also comes the announcement of Gladskin’s newly branded Eczemact™ skincare line—a comprehensive skin- and body-care system designed for people with eczema-prone skin. The Eczemact™ line features the same great Gladskin formulas in new packaging, in addition to new products. For more details, visit Gladskin.com.

[1] National Eczema Association, https://nationaleczema.org/research/eczema-facts/

About Gladskin

Gladskin is on a mission to improve quality of life for millions of people living with inflammatory skin conditions worldwide. Our revolutionary non-prescription products for eczema and rosacea use patented endolysin science to balance the skin microbiome and restore skin health. Gladskin is a subsidiary of the European biotechnology company Micreos Group, a Dutch / Swiss biotechnology group that has pioneered the development of phage and endolysin technology as a sustainable alternative to antibiotics. Learn more at gladskin.com.

Share article on social media or email:

American Gene Technologies® CEO Jeff Galvin Wins Life Sciences Voice Top Industry Leaders Award


News Image

This is a wonderful honor, made possible thanks to the stellar collaboration and unwavering commitment of my talented colleagues and team members here at American Gene. -Jeff Galvin, CEO of AGT™

Jeff Galvin, CEO and founder of American Gene Technologies®, a clinical-stage biotechnology company based in Rockville, Maryland, has been awarded the Life Sciences Voice Top Industry Leaders Award. The award recognizes the most dynamic leaders in the life sciences industry, who are making the biggest impact in delivering transformation that is moving the industry forward. Life Sciences Voice lauds these winners as the industry’s most creative minds working on important initiatives and delivering extraordinary results.

“This is a wonderful honor, made possible thanks to the stellar collaboration and unwavering commitment of my talented colleagues and team members here at American Gene™,” said Galvin. “I am thrilled to receive this recognition for the work we have been doing using gene therapy to find cures for some of the world’s worst diseases.”

Life Sciences Voice describes this recognition as “the most prestigious leadership award in the life sciences industry.” Jean Coolidge, editor-in-chief added, “The life sciences industry, and healthcare landscape in general, continues to evolve rapidly. It has become critical for the life sciences companies and their leaders to adapt quickly and respond to the future needs of the customers.”

LSV also noted: “These leaders continue to find innovative ways to drive excellence in their field of work. They fully understand how science must be mapped to business and patient needs and are able to bring value to their stakeholders — patients, employees, healthcare partners, investors, and others.”

Having had a successful career in Silicon Valley in the ‘80s and ’90s, Galvin opted for an early retirement in 2002. But 15 years ago, National Institutes of Health researcher Roscoe Brady, MD, Ph.D, introduced him to the potential of viral vectors. Brady showed him there was a way to “repurpose” viruses from delivering disease-causing genetic elements, into delivery vehicles that could bring “good” elements into the body that fight disease. Galvin was hooked. He came out of retirement and founded American Gene.

Having been part of the computer software industry for nearly 30 years, Galvin saw many parallels between a human cell’s DNA “code” and a computer’s operating software. Viewing Dr. Brady’s work from a computer-software perspective, Galvin realized Dr. Brady had just revealed the potential of using viruses as “diskettes” that could deliver new “genetic software” into the DNA of cells to manipulate the drivers (genes) of everything in the human body.

Galvin saw Dr. Brady’s breakthrough as the beginning of a new life sciences technology revolution on a global scale, enabling gene therapy to develop along a technology “curve” that would lead to cures for thousands of diseases, including cancer. Galvin foresaw this nearly 10 years before the biotech and pharma industries began to think about the power and possibilities of gene and cell therapy.

At American Gene, Galvin prioritized the goal of curing HIV through gene therapy. He believes gene therapy can free people living with HIV from relying on lifelong antiretroviral treatments and give them permanent immunity with no chance of contracting HIV again.

Galvin views curing HIV as a proof-of-concept for American Gene’s platform, which could reduce the time and cost of developing disease-curing gene therapies by over 90% from current standards. The approach could eventually solve patient issues across infectious diseases, monogenic disorders, and cancers that affect the lives of billions of people worldwide.

About American Gene Technologies

American Gene Technologies is a gene therapy company with a proprietary gene-delivery platform for rapid development of gene therapies to cure infectious diseases, cancers, and inherited disorders. Its mission is to transform people’s lives through genetic medicines that rid the body of disease. Safety and durability data from American Gene Technologies’ Phase 1 HIV gene therapy clinical trial is published in the Frontiers in Medicine journal and a final report is being prepared for regulatory submission. In addition, the company has been granted four patents for the technology used to make AGT103-T and 11 patents for its unique immuno-oncology approach to stimulate gamma-delta (γδ) T cells to destroy a variety of solid tumors. American Gene Technologies has developed a synthetic gene for treating Phenylketonuria (PKU), a debilitating inherited disease. The company’s treatment for PKU has been granted Orphan Drug Designation by the Food and Drug Administration (FDA), and it is expected to reach the clinic in 2023.

Video About American Gene Technologies’ Work: https://youtu.be/fiA2s7JCkJ8

Share article on social media or email:

Sleeplay Announces New Mobile App Ahead of World Sleep Day


“Adapting to current technology is crucial for meeting customers where they are and increasing their accessibility to innovative products and services that improve quality of life and revolutionize sleep,” said Aaron Fuhrman, Founder and Director of Sleeplay.

Today, Sleeplay, a modern CPAP company connecting people to industry leading experts and products for the deepest, best sleep possible, launched the Sleeplay mobile application. It is now available via the App Store and Google Play Store, which will expand accessibility to its luxury sleep products, CPAP equipment and connect customers with medical experts. To celebrate the app launch and World Sleep Day on March 18, Sleeplay is offering 25% off with the promo code “APPLAUNCH25”.

“We’re thrilled to announce the launch of the Sleeplay app and expand our foothold in the CPAP and luxury sleep space,” said Aaron Fuhrman, Founder and Director of Sleeplay. “Adapting to current technology is crucial for meeting customers where they are and increasing their accessibility to innovative products and services that improve quality of life and revolutionize sleep.”

The new app will give customers access to Online CPAP Expert support, user-friendly upload RX for fast order placement, visibility into past orders and focused on removing the hassle in all things sleep, wellness and comfort. The app will provide customers with another avenue to obtain the life-changing equipment and accessories that aid the 22 million adult Americans suffering from sleep apnea or other related medical issues. Featuring hundreds of curated products for those with sleep apnea and without, like travel-size CPAP machines, CPAP cleaners, filters, tubings and CPAP batteries for camping, the new app will become the ultimate sleep playground destination.

Customers can download the IOS Sleeplay app here and the Android Sleeplay app here. To learn more about Sleeplay, visit sleeplay.com.

###

About Sleeplay

Sleeplay is a modern CPAP destination dedicated to connecting the next generation with experts and products, from CPAP machines and cleaners to masks and humidifiers, for the deepest, best sleep possible. Through its white-glove customer service and innovative smartphone app and website, Sleeplay removes the headache and hassle in discovering high-quality products by easily connecting customers with CPAP Expert and respiratory therapists to help them better understand their diagnosis and sleep needs. Sleeplay services customers looking to optimize their rest, relaxation and recovery through benefits such as digital prescription uploads, complimentary equipment troubleshooting, financing and effective diagnostic quizzes. Sleeplay proudly partners with American Homecare Equipment, Inc., a trusted member of the industry for over 30 years, and offers products from leading brands such as ResMed, Fisher & Paykel and Philips Respironics. For additional information, visit sleeplay.com.

Share article on social media or email:

Mediliant Group Announces New President of Their Facility in Plymouth, Indiana


News Image

In a continued effort to respond to customer needs and further boost company momentum, leaders in medical device contract manufacturing, Mediliant Group, has appointed industry expert Jason Ratcliffe as the new President of the organization’s CTE facility in Plymouth, Indiana.

Mr. Ratcliffe has an extensive career in the manufacturing industry, working in several key positions of increasing responsibility in the automotive, defense, and medical device industries. Based in Detroit, Michigan, Jason’s career began in the automotive industry where he spent a decade in various roles from production management, and engineering before specializing in lean manufacturing.

From here, Jason moved to Beaver Aerospace & Defense where he was the General Manager of multiple sites. Jason’s success at Beaver was a springboard into the medical device industry where he enjoyed a period of huge success as the GM of Orchid’s flagship facility, Bridgeport as well as two smaller sites, ultimately responsible for over $150m of revenue and 700 plus employees. Jason’s experience extends into procurement and sourcing, international business leadership, and people development. In his spare time, he is an owner in his church, an attentive husband and father, and an active DJ.

“We are delighted to have Jason join our team and lead our operational efforts at CTE. He is a result-orientated leader who facilitates strong, high-performing teams that have an extremely customer-focused mindset. We expect Jason to build on the excellent reputation of CTE and the strong foundations the current leadership team provides there, to deliver our strategy to become a top-tier Spine, Trauma, & Extremities contract manufacturer.” - Matt Burba, Mediliant Group CEO.

Jason’s expertise, considerable leadership and management skills, and ability to work in a high-pressure environment make him the ideal person to take Mediliant Group’s CTE facility to the next level. As the company continues to build momentum, expand capabilities, and enhance customer experiences, the growth of the leadership team plays an important role in the overall success.

For more information on Mr. Ratcliffe and the continued growth of the Mediliant Group, visit mediliant.com.

Share article on social media or email:

FDA Grants First Marketing Rights for Anthrax Point-of-Care Test to InBios


Active Anthrax Detect™ Plus Rapid Test

“A fast, accurate test is needed to prepare for a potential bioterrorism attack or outbreak. Our test could play a critical role in thwarting any suspicious activities early on.”

Given the possible severity of anthrax infection, early and fast diagnosis is key. InBios International, Inc., a leading developer of diagnostic tests for emerging infectious diseases and biothreats, has been granted the U.S. Food and Drug Administration’s (FDA) first marketing rights for an anthrax point-of-care (POC) test. This approval was granted through the FDA’s De Novo process for new medical devices or technology where there is no comparable device on the market. InBios’ Active Anthrax Detect™ Plus Rapid Test for pulmonary anthrax is for use as an aid in the diagnosis of inhalation anthrax, which occurs by breathing in anthrax spores and is the deadliest form of the disease. This test produces results in about 20 minutes and is intended for use by military personnel, medical and/or healthcare professionals only.

This in vitro immunochromatographic assay provides visual and rapid qualitative detection of the Bacillus anthracis lethal factor protein and can be used to test serum and venous whole blood (dipotassium EDTA, sodium citrate and sodium heparin) from individuals who have signs and symptoms consistent with inhalation anthrax and a likelihood of exposure. While a positive Active Anthrax Detect™ Plus Rapid Test result is presumptively diagnostic for B. anthracis infection, diagnosis of infection must be based on history, signs, symptoms, exposure likelihood, and additional laboratory evidence.

Clinical performance determined that the test had a negative percent agreement (NPA) of 100% and a positive percent agreement (PPA) of >98%. The specificity study (NPA) was conducted at three POC clinical sites in the United States, while the sensitivity (PPA) of the test was evaluated using contrived positive serum samples.

“With ease of dispersal and a high mortality rate, inhalation anthrax is a great threat to the security and safety of the world,” said Syamal Raychaudhuri, PhD, InBios Chief Scientific Officer. “A fast, accurate test is needed to prepare for a potential bioterrorism attack or outbreak. Our test could play a critical role in thwarting any suspicious activities early on.”

The De Novo classification for the Active Anthrax Detect™ Plus Rapid Test was supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201700029C awarded in 2017. Additionally, the Centers for Disease Control and Prevention (CDC) provided significant expertise and resources, which contributed toward the development of the Active Anthrax Detect™ Plus Rapid Test.

Anthrax is a zoonotic bacterial disease caused by Bacillus anthracis, a gram-positive, spore-forming bacterium commonly found in the soil of disease-endemic areas. The disease presents with non-specific symptoms that cannot easily be distinguished from many common diseases. Although anthrax infection is rare, risk of infection remains, whether due to bioterrorism or injectional drug usage. For more information, visit http://www.cdc.gov/anthrax.

About InBios: InBios International Inc. specializes in the design, development and manufacture of diagnostic assays for emerging infectious diseases and biothreats. InBios has several products on the market, including point-of-care tests and an over-the-counter test for COVID-19. Located in Seattle, Washington, InBios offers superior quality products which are accurate, easy to use and cost-effective. InBios is GMP compliant, FDA registered, USDA licensed, and ISO 13485:2016 certified. For more information, visit http://www.inbios.com

Share article on social media or email: